Jason R Brown

18PUBLICATIONS
99CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsEpigenetics (incl. genome methylation and epigenomics)Central and Eastern European languages (incl. Russian)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|May 21, 2026
Variant allele frequency as a potential marker in response to frontline systemic therapy for patients with locally advanced and metastatic urothelial carcinoma.

|Feb 27, 2026
Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer.

Abby L Grier, Jeffrey Y Zhong, Spyridon Basourakos

|Feb 09, 2026
Immune checkpoint inhibitors in urothelial carcinoma: a practical framework for patient selection, toxicity management, response assessment, and treatment sequencing.

Abdul Rahman Al Armashi, Jenny Gong, Pedro Barata

|Dec 20, 2025
Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials.

Georges Gebrael, Neeraj Agarwal, Alicia K Morgans

|Dec 09, 2025
Toward a better pan-tumor predictive signature for unleashing precision immuno-oncology.

Jason R Brown, Guru Sonpavde

|Nov 06, 2025
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation.

Capucine Baldini, Loic Verlingue, Vincent Goldschmidt

Pageof 3

Frequent Collaborators

6 joint publications

Albert Jang

5 joint publications

Pedro C Barata

4 joint publications

Laura Bukavina

3 joint publications

Angela Y Jia